Home › Macular Degeneration › NCT02253030
OCT Angiography in Wet AMD
Optical Coherence Tomography Angiography in Neovascular Age-related Macular Degeneration
Who can join
Ages 50 to 100 · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria (Groups with wet AMD): * Adults aged 50 and older with clinical findings of treatment-naïve (never treated) neovascular AMD with active new blood vessel growth confirmed by clinical testing will be considered Inclusion Criteria (Group with healthy eyes) * No evidence of retinal disease * Refractive error greater than +3.00 diopters or -7.00 diopters (glasses Rx) * No recent eye surgery in the last 4 months * No significant cataract to interfere with the quality of the imaging Exclusion Criteria (All Groups): * Inability to give informed consent * Significant kidney disease * Blood pressure greater than 180/110 * Previous macular laser treatment * Inability to maintain stable fixation during OCT imaging * Visual acuity worse than 20/200
About the study
The primary goals of this study are to use optical coherence tomography (OCT) angiography (blood vessel mapping) to:
1. diagnose the presence of new blood vessels in wet age-related macular degeneration (AMD) 2. evaluate patients undergoing treatment for wet AMD 3. determine if reduced flow to the choroid is a risk factor for developing wet AMD.
What is being tested
- Optical Coherence Tomography (device)
Sponsor: Oregon Health and Science University · Participants: 160 · Started: 2014-09
Contact the study team
- George Pacheco, COA · Phone: 503-494-7398
- Denny Romfh, OD · Phone: 503-494-4351
Official record on ClinicalTrials.gov — NCT02253030
Locations in the U.S.
| Oregon | Casey Eye Institute, Oregon Health & Science University, Portland |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.